Pliant Therapeutics
PLRX1.0651.43% ( +0.015 )
Pliant Therapeutics (PLRX)
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of so...
- Open
- 1.060
- High
- 1.070
- Low
- 1.050
- Prev. Close
- 1.050
- Volume
- 82.62K
- Turnover
- 87.63K
- Avg Price
- 1.061
- Bid/Ask Ratio
- --
- Amplitude
- 1.90%
- 52wk High
- 1.950
- Volume Ratio
- 0.51
- Turnover Ratio
- 0.14%
Pliant Therapeutics Analyst Rating
View MoreForecast & Rating
Jun 29, 2026Price forecast
$2.50134.74%
Forecast & RatingHold
5analysts
- Strong buy0.00%
- Buy0.00%
- Hold80.00%
- Sell0.00%
- Strong sell20.00%
News
- Market Beat · 1 day ago, 02:13 AM
Pliant Therapeutics, Inc. $PLRX Stock Position Raised by ADAR1 Capital Management LLC
- Simplywall · Jul 14 at 12:08 PM
Coastal Financial (CCB) Could Be 52% Undervalued On Pliant US Partnership
- PUBT · Jul 13 at 03:33 PM
Pliant Therapeutics director Flavia Borellini files initial beneficial ownership statement
- PUBT · Jul 13 at 08:16 AM
Pliant Therapeutics appoints Flavia Borellini, Robert Iannone to board
- StockTitan · May 21 at 08:30 AM
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting | PLRX Stock News
- StockTitan · May 15 at 01:25 AM
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board | PLRX Stock News
